> "DSMB externalisations of concerns are deeply unusual for multinational pharma companies and suggest an extraordinary high level of friction between the DSMB

> "DSMB externalisations of concerns are deeply unusual for multinational pharma companies and suggest an extraordinary high level of friction between the DSMB and the sponsor,' Citi analysts said in a note." It sounds like they're not getting the type of collaboration they want from AZ, so they've raised the stakes.